An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Abstract Background The long-term efficacy and safety of the 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) and 3-drug single-tablet regimens recommended for antiretroviral therapy (ART)-naive people with HIV-1 (PWH) have yet to be compared directly in clinical trials. This indirect treatment...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lee A. Evitt, Sakina Nanji, Richard A. Grove, Chinyere Okoli, Jean van Wyk, Sonya J. Snedecor
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-03-01
Series:	AIDS Research and Therapy
Assuntos:	Antiretroviral agents HIV-1 infection Dolutegravir Lamivudine Bictegravir Emtricitabine
Acceso en liña:	https://doi.org/10.1186/s12981-023-00507-1
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!